Indian study finds single-dose HPV jab enough to prevent cervical cancer – Gudstory

The study, conducted in hospitals across India, found that 10 years after vaccination, a high proportion of single dose recipients still had antibody titers against HPV types 16 and 18, with the same proportion among 10–14 year olds. There was a little more than those. Age 15-18.

The main focus of the research is to study the long-term antibody response after a single dose of the HPV vaccine.

The study showed that a single dose jab, with an extended catch-up until the age of 20, is more likely to reduce the lifetime risk of cervical cancer and eliminate the disease than giving two doses to pre-teen girls. Will have a significant impact.

“There was a vaccine available earlier in India which is Gardasil (developed by Merck & Co), and now there is an indigenous vaccine which is similar, named Survavac. The single dose vaccine (Gardasil) is still effective even if given up to the age of 20 years. However, this is not the same case for Cervavac (which recommends two doses),” said Dr Neerja Bhatla, head of Obstetrics and Gynecology, AIIMS Delhi and co-author of the study.

The study was conducted on 2,135 women who were followed over 10 years by a group of unmarried girls aged 10-18 years who received one, two or three doses of HPV vaccines.

The aim of the study was to compare antibody responses between younger and older groups 10 years after vaccination and to evaluate the effect of the onset of sexual activity on antibody levels.

According to experts, the durability of the immune response after a single dose of HPV vaccine is an important factor to guide policies, especially when the upper age for vaccination is raised to 20 years.

“The humoral response depends on age at the time of vaccination; “Antibody titers after two doses of the bivalent vaccine in women aged 18-25 years were recorded to be only about half of the antibody titers achieved in those aged 10-17 years,” the study said.

Cervical cancer is the second most common cancer among women in India. It is considered one of the most preventable cancers worldwide, a result of the right policy measures.

The World Health Organization (WHO) recommends one or two doses for girls aged 9–14 years.